ATRA therapy restores normal renal function and renal reserve and prevents renal failure

Annals of the Academy of Medicine Singapore

Volumn 34, Issue 1, 2005, Pages 52-59

  Woo, Keng Thye ^a   Lau, Y K ^a   Chan, C M ^a   Wong, K S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Angiotensin receptor antagonist; Creatinine clearance; Hyperfiltration; Kidney failure; Renal reserve

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PROTEINURIA; SIDE EFFECT; SODIUM RESTRICTION; TREATMENT OUTCOME;

EID: 15044357744     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000;58:2485-91.
2. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877-89.
3. Perna A Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996;27:34-41.
4. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995;92:10663-7.
5. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998;31:684-91.
6. Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 1999;14:98-104.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
8. Brenner BM, Meyer TW, Hosteller TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-9.
9. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994;45:537-43.
10. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17:1413-8.
11. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24. Erratum in: Lancet 2003;361:1230.
12. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatmentofangiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24. Erratum in: Lancet 2003;361:1230.
13. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawaihi H, et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999;55:877-89.
14. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995;92:10663-7.